Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible

Bone

Volumn 67, Issue , 2014, Pages 269-280

  Zhuo, Y ^a   Gauthier, J Y ^b   Black, W C ^c   Percival, M D ^d   Duong, L T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pharmascience   (Canada)

^c Kaneq Pharma Inc   (Canada)

^d Inception Sciences Canada Inc ^*  (Canada)

Author keywords

Bone resorption; Cathepsin K inhibitor; Osteoclast; Resorption lacunae; Ruffled border

Indexed keywords

ALENDRONIC ACID; BODIPY L 226; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; CATHEPSIN K INHIBITOR; CELL MARKER; LYSOSOME ENZYME; N CYANOMETHYL 4 METHYL 2 [[2,2,2 TRIFLUORO 1 [4 (4 METHANESULFONYLPHENYL)PHENYL]ETHYL]AMINO]PENTANAMIDE; ODANACATIB; PROTEIN 1 CTP; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; L-873724;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE SLICE; CELL MIGRATION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IC50; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; PREVENTION AND CONTROL; SCANNING ELECTRON MICROSCOPY; ULTRASTRUCTURE; WESTERN BLOTTING;

BIPHENYL COMPOUNDS; BLOTTING, WESTERN; BONE RESORPTION; CATHEPSIN K; CELLS, CULTURED; HUMANS; MICROSCOPY, ELECTRON, SCANNING; OSTEOCLASTS;

EID: 84911883350     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.07.013     Document Type: Article

References (32)

1. Boyce B.F. J Bone Miner Res 2013, 28(4):711-722.
2. Andersen T.L., Sondergaard T.E., Skorzynska K.E., Dagnaes-Hansen F., Plesner T.L., Hauge E.M., et al. Am J Pathol 2009, 174(1):239-247.
3. Sims N.A., Martin T.J. Bonekey Rep 2014, 3:481.
4. Duong L.T., Rodan G.A. Rev Endocr Metab Disord 2001, 2(1):95-104.
5. Coxon F.P., Taylor A. Semin Cell Dev Biol 2008, 19(5):424-433.
6. Baron R., Ferrari S., Russell R.G. Bone 2011, 48(4):677-692.
7. Rodan G., Reszka A., Golub E., Rizzoli R. Curr Med Res Opin 2004, 20(8):1291-1300.
8. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. J Bone Miner Res 1997, 12(10):1700-1707.
9. Duong le T. Bonekey Rep 2012, 1:67.
10. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., et al. J Biol Chem 1996, 271(21):12511-12516.
11. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Science (New York, NY) 1996, 273(5279):1236-1238.
12. Schilling A.F., Mulhausen C., Lehmann W., Santer R., Schinke T., Rueger J.M., et al. Osteoporos Int 2007, 18(5):659-669.
13. Pennypacker B., Shea M., Liu Q., Masarachia P., Saftig P., Rodan S., et al. Bone 2009, 44(2):199-207.
14. Leung P., Pickarski M., Zhuo Y., Masarachia P.J., Duong L.T. Bone 2010, 49(4):623-635.
15. Gauthier J.Y., Chauret N., Cromlish W., Desmarais S., Duong le T., Falgueyret J.P., et al. Bioorg Med Chem Lett 2008, 18(3):923-928.
16. Masarachia P.J., Pennypacker B.L., Pickarski M., Scott K.R., Wesolowski G.A., Smith S.Y., et al. J Bone Miner Res 2012, 27(3):509-523.
17. Pennypacker B., Chen C., Zhuo Y., Pickarski M., Duong L.T. Comparison of the efficacy of odanacatib or alendronate on bone remodeling and biomechanical properties of the lumbar spine in estrogen-deficient rhesus monkeys. J Bone Miner Res 2011, 26(Suppl. 1). [Available at http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx. Accessed (April 23rd, 2014)].
18. Langdahl B., Binkley N., Bone H., Gilchrist N., Resch H., Rodriguez Portales J., et al. J Bone Miner Res 2012, 27(11):2251-2258.
19. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. J Bone Miner Res 2011, 26(2):242-251.
20. Falgueyret J.P., Black W.C., Cromlish W., Desmarais S., Lamontagne S., Mellon C., et al. Anal Biochem 2004, 335(2):218-227.
21. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., et al. Proc Natl Acad Sci U S A 1999, 96(1):133-138.
22. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., et al. J Bone Miner Res 2003, 18(5):859-867.
23. Stoch S.A., Zajic S., Stone J., Miller D.L., Van Dyck K., Gutierrez M.J., et al. Clin Pharmacol Ther 2009, 86(2):175-182.
24. Jobke B., Milovanovic P., Amling M., Busse B. Bone 2014, 59C:37-43.
25. Ljusberg J., Wang Y., Lang P., Norgard M., Dodds R., Hultenby K., et al. J Biol Chem 2005, 280(31):28370-28381.
26. Samanna V., Ma T., Mak T.W., Rogers M., Chellaiah M.A. J Cell Physiol 2007, 213(3):710-720.
27. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Osteoporos Int 2008, 19(6):733-759.
28. Kassahun K., Black W.C., Nicoll-Griffith D., McIntosh I., Chauret N., Day S., et al. Drug Metab Dispos 2011, 39(6):1079-1087.
29. Kassahun K., McIntosh I., Koeplinger K., Sun L., Talaty J.E., Miller D.L., et al. Drug Metab Dispos 2014, 42(5):818-827.
30. Bonnick S., De Villiers T., Odio A., Palacios S., Chapurlat R., Dasilva C., et al. J Clin Endocrinol Metab 2013, 98(12):4727-4735.
31. Sims N.A., Ng K.W. Curr Osteoporos Rep 2014, 12(1):98-106.
32. Lotinun S., Kiviranta R., Matsubara T., Alzate J.A., Neff L., Luth A., et al. J Clin Invest 2013, 123(2):666-681.